U.S., Feb. 14 -- ClinicalTrials.gov registry received information related to the study (NCT07408856) titled 'CAN1012 in OED, DCIS, and LCIS.' on Feb. 03.
Brief Summary: This is a Phase I/Ib study evaluating CAN1012 in patients with oral epithelial dysplasia, ductal carcinoma in situ, and lobular carcinoma in situ.
Study Start Date: May, 2026
Study Type: INTERVENTIONAL
Condition:
Oral Epithelial Dysplasia
Ductal Carcinoma in Situ
Lobular Carcinoma in Situ
Intervention:
DRUG: CAN1012 (.2 mL)
CAN1012 is a IFN-a biased, long-acting, highly selective TLR7 agonist, which acts as an immune modulator capable of priming both innate and adaptive immunity against tumors. CAN1012 will be administered as an injection directly into the target les...